GBIM Overview
Upcoming Projects (GBIM)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (GBIM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (GBIM)
-
Phase 2 study of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the treatment of Chronic HBV to complete June 2018
Tickers: GILD, GBIM
Occurred on: Jun 15, 2018 -
Phase 2 interim data of GI-6207 for medullary thyroid cancer due Jan 2019 - Acquired by NantCell, Inc.
Ticker: GBIM
Occurred on: Mar 23, 2017 -
Phase 2 study of GI-6301 treatment on patients with Chordoma expected to complete March 2019 - Acquired by NantCell, Inc.
Ticker: GBIM
Occurred on: Mar 23, 2017 -
Phase 2 48-week results of GS-4774 - 0101 trial - for chronic hepatitis B infection are expected to be available 2H 2016
Ticker: GBIM
Occurred on: Oct 03, 2016 -
GlobeImmune Announces Delisting and Deregistration of Common Stock
Ticker: GBIM
Occurred on: Jul 05, 2016 -
GlobalImmune Enrolling Patients in Phase 2 Study for GI-6301 Treatment of Chordoma
Ticker: GBIM
Occurred on: Feb 21, 2016
Strategic Initiatives (GBIM)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
